Veru is trading 5.1% up today at $2.38, continuing a multi-day rebound following its clinical supply agreement with Novo Nordisk for the PLATEAU Phase 2b obesity trial.
- The agreement secures Wegovy for use in combination with enobosarm, Veru's lead candidate designed to preserve muscle mass during weight loss.
- The broader biotech sector is also rallying on strong earnings and upbeat risk appetite, providing additional tailwinds for the share price.
- Investor sentiment remains high regarding the enobosarm obesity program as the company progresses through its clinical milestones.